Rate of primary refractory disease in B and T-Cell non-Hodgkin's Lymphoma: Correlation with long-term survival

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Tarella, Corrado ^a,b   Gueli, Angela ^a,b   Delaini, Federica ^c   Rossi, Andrea ^c   Barbui, Anna Maria ^c   Gritti, Giuseppe ^c   Boschini, Cristina ^c   Caracciolo, Daniele ^a,d   Bruna, Riccardo ^a,b   Ruella, Marco ^a,b   Gottardi, Daniela ^a,b   Passera, Roberto ^a   Rambaldi, Alessandro ^d  

^a UNIVERSITY OF TURIN   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

^c Hematology and Bone Marrow Transplant Units A O Papa Giovanni XXIII   (Italy)

^d Division of Hematology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOGRAFT; BONE MARROW; CANCER DIAGNOSIS; CHEMOSENSITIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; INCIDENCE; INTENSIVE CARE; ITALY; LARGE CELL LYMPHOMA; LIFE EXPECTANCY; LONG TERM SURVIVAL; LYMPHATIC SYSTEM DISEASE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIMARY REFRACTORY DISEASE; RETROSPECTIVE STUDY; SEX DIFFERENCE; T CELL LYMPHOMA; TREATMENT RESPONSE; DRUG RESISTANCE; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MIDDLE AGED; MULTIVARIATE ANALYSIS; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84907478476     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106745     Document Type: Article

References (40)

1. Mahadevan D, Fisher RI (2011) Novel therapeutics for aggressive non-Hodgkin's lymphoma. J Clin Oncol 29: 1876-1884.
2. Armitage JO (2012) The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87: 511-519.
3. Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, et al. (2013) Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood 122: 981-987.
4. Cabanillas F (2011) Non-Hodgkin's lymphoma: the old and the new. Clin Lymphoma Myeloma Leuk 11 Suppl 1: S87-90.
5. Moskowitz C (2012) Diffuse large B cell lymphoma: how can we cure more patients in 2012? Best Pract Res Clin Haematol 25: 41-47.
6. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, et al. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937-1947.
7. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, et al. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumorinfiltrating immune cells. N Engl J Med 351: 2159-2169.
8. Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, et al. (2010) B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 34: 327-340.
9. Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, et al. (2011) Double-hit B-cell lymphomas. Blood 117: 2319-2331.
10. Royo C, Salaverria I, Hartmann EM, Rosenwald A, Campo E, et al. (2011) The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol 21: 322-334.
11. Piccaluga PP, Fuligni F, De Leo A, Bertuzzi C, Rossi M, et al. (2013) Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol 31: 3019-3025.
12. Sawas A, Diefenbach C, O'Connor OA (2011) New therapeutic targets and drugs in non-Hodgkin's lymphoma. Curr Opin Hematol 18: 280-287.
13. Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, et al. (2012) A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer 118: 3128-3134.
14. Leskov I, Pallasch CP, Drake A, Iliopoulou BP, Souza A, et al. (2013) Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies. Oncogene 32: 1066-1072.
15. Cuccuini W, Briere J, Mounier N, Voelker HU, Rosenwald A, et al. (2012) MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or RDHAP followed by BEAM plus autologous stem cell transplantation. Blood 119: 4619-4624.
16. Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, et al. (2012) A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 97: 758-765.
17. d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, et al. (2012) Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 30: 3093-3099.
18. Galli M, Nicolucci A, Valentini M, Belfiglio M, Delaini F, et al. (2005) Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma. Haematologica 90: 1643-1649.
19. Tarella C, Zanni M, Magni M, Benedetti F, Patti C, et al. (2008) Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: A multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol 26: 3166-3175.
20. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242.
21. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, et al. (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23: 5027-5033.
22. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328: 1002-1006.
23. Pfreundschuh M, Kuhnt E, Trümper L, Ö sterborg A, Trneny M, et al. (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. The Lancet Oncology 12: 1013-1022.
24. Lunning MA, Vose JM (2012) Management of indolent lymphoma: where are we now and where are we going. Blood Rev 26: 279-288.
25. Zinzani PL, Marchetti M, Billio A, Barosi G, Carella AM, et al. (2013) SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma. Am J Hematol 88: 185-192.
26. Sweetenham JW (2008) Highly aggressive lymphomas in adults. Hematol Oncol Clin North Am 22: 965-978, ix.
27. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, et al. (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25: 579-586.
28. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
29. Cox DR (1972) Regression Models and Life-Tables. Journal of the Royal Statistical Society Series B (Methodological) 34: 187-220.
30. Li ZM, Huang JJ, Xia Y, Sun J, Huang Y, et al. (2012) Blood lymphocyte-tomonocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One 7: e41658.
31. Rambaldi A, Boschini C, Gritti G, Delaini F, Oldani E, et al. (2013) The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large Bcell lymphoma when rituximab is added to chemotherapy. Am J Hematol 88: 1062-1067.
32. Surveillance, Epidemiology, and End Results (SEER) Program. SEER∗Stat Database: Incidence-SEER Research Data (1973-2010). National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission. Available: http://seer.cancer.gov/data/.
33. Elstrom RL, Andemariam B, Martin P, Ruan J, Shore TB, et al. (2012) Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leuk Lymphoma 53: 1469-1473.
34. Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Brière J, et al. (1998) Prognostic Significance of T-Cell Phenotype in Aggressive Non-Hodgkin's Lymphomas. Blood 92: 76-82.
35. Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, et al. (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral Tcell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110: 2316-2323.
36. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, et al. (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101: 4279-4284.
37. Muller C, Murawski N, Wiesen MH, Held G, Poeschel V, et al. (2012) The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 119: 3276-3284.
38. Tarella C, Passera R, Magni M, Benedetti F, Rossi A, et al. (2011) Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: A 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 29: 814-824.
39. Maloney D (2008) Allogeneic transplantation following nonmyeloablative conditioning for aggressive lymphoma. Bone Marrow Transplant 42 Suppl 1: S35-S36.
40. Schneider CK, Vleminckx C, Gravanis I, Ehmann F, Trouvin JH, et al. (2012) Setting the stage for biosimilar monoclonal antibodies. Nat Biotechnol 30: 1179-1185.